Mirabegron (YM178)CAS# 223673-61-8 |
- Guanfacine hydrochloride
Catalog No.:BCC1609
CAS No.:29110-48-3
- (R,R)-Formoterol
Catalog No.:BCC1293
CAS No.:67346-49-0
- Doxazosin Mesylate
Catalog No.:BCC1257
CAS No.:77883-43-3
- Medetomidine
Catalog No.:BCC1736
CAS No.:86347-14-0
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 223673-61-8 | SDF | Download SDF |
PubChem ID | 9865528 | Appearance | Powder |
Formula | C21H24N4O2S | M.Wt | 396.51 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | DMSO : 100 mg/mL (252.20 mM; Need ultrasonic) | ||
Chemical Name | 2-(2-amino-1,3-thiazol-4-yl)-N-[4-[2-[[(2R)-2-hydroxy-2-phenylethyl]amino]ethyl]phenyl]acetamide | ||
SMILES | C1=CC=C(C=C1)C(CNCCC2=CC=C(C=C2)NC(=O)CC3=CSC(=N3)N)O | ||
Standard InChIKey | PBAPPPCECJKMCM-IBGZPJMESA-N | ||
Standard InChI | InChI=1S/C21H24N4O2S/c22-21-25-18(14-28-21)12-20(27)24-17-8-6-15(7-9-17)10-11-23-13-19(26)16-4-2-1-3-5-16/h1-9,14,19,23,26H,10-13H2,(H2,22,25)(H,24,27)/t19-/m0/s1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Mirabegron (YM178) Dilution Calculator
Mirabegron (YM178) Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.522 mL | 12.61 mL | 25.22 mL | 50.4401 mL | 63.0501 mL |
5 mM | 0.5044 mL | 2.522 mL | 5.044 mL | 10.088 mL | 12.61 mL |
10 mM | 0.2522 mL | 1.261 mL | 2.522 mL | 5.044 mL | 6.305 mL |
50 mM | 0.0504 mL | 0.2522 mL | 0.5044 mL | 1.0088 mL | 1.261 mL |
100 mM | 0.0252 mL | 0.1261 mL | 0.2522 mL | 0.5044 mL | 0.6305 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Mirabegron activates the β3 adrenergic receptor in the detrusor muscle in the bladder, which leads to muscle relaxation and an increase in bladder capacity.
- Collagen proline hydroxylase inhibitor
Catalog No.:BCC1494
CAS No.:223666-07-7
- Collagen proline hydroxylase inhibitor-1
Catalog No.:BCC1495
CAS No.:223663-32-9
- K-115 free base
Catalog No.:BCC5501
CAS No.:223645-67-8
- Tiadinil
Catalog No.:BCC8070
CAS No.:223580-51-6
- CPA inhibitor
Catalog No.:BCC1500
CAS No.:223532-02-3
- YM 58483
Catalog No.:BCC7817
CAS No.:223499-30-7
- ONO 4817
Catalog No.:BCC2375
CAS No.:223472-31-9
- GLP-2 (human)
Catalog No.:BCC5891
CAS No.:223460-79-5
- FG2216
Catalog No.:BCC6402
CAS No.:223387-75-5
- Polygalacic acid
Catalog No.:BCN5898
CAS No.:22338-71-2
- Grandifloric acid
Catalog No.:BCN4669
CAS No.:22338-69-8
- Grandiflorenic acid
Catalog No.:BCN4670
CAS No.:22338-67-6
- Eupatilin
Catalog No.:BCN2336
CAS No.:22368-21-4
- 4-Methoxysalicylic acid
Catalog No.:BCN7783
CAS No.:2237-36-7
- Sodium Monensin
Catalog No.:BCC5319
CAS No.:22373-78-0
- NPE-caged-HPTS
Catalog No.:BCC5950
CAS No.:223759-19-1
- Bestatin trifluoroacetate
Catalog No.:BCC3909
CAS No.:223763-80-2
- Pedalitin
Catalog No.:BCN3954
CAS No.:22384-63-0
- Serratenediol
Catalog No.:BCN5061
CAS No.:2239-24-9
- 3,8-Di-O-methylellagic acid
Catalog No.:BCN5062
CAS No.:2239-88-5
- Aristola-1(10),8-dien-2-one
Catalog No.:BCN7608
CAS No.:22391-34-0
- Cyclobuxine D
Catalog No.:BCC9221
CAS No.:2241-90-9
- 3-Epiturraeanthin
Catalog No.:BCN5063
CAS No.:22415-24-3
- Siramesine hydrochloride
Catalog No.:BCC5134
CAS No.:224177-60-0
Absorption, metabolism and excretion of [(14)C]mirabegron (YM178), a potent and selective beta(3)-adrenoceptor agonist, after oral administration to healthy male volunteers.[Pubmed:22269146]
Drug Metab Dispos. 2012 Apr;40(4):815-24.
The mass balance and metabolite profiles of 2-(2-amino-1,3-thiazol-4-yl)-N-[4-(2-{[(2R)-2-hydroxy-2-phenylethyl]amino}ethyl)[ U-(14)C]phenyl]acetamide ([(14)C]mirabegron, YM178), a beta(3)-adrenoceptor agonist for the treatment of overactive bladder, were characterized in four young, healthy, fasted male subjects after a single oral dose of [(14)C]mirabegron (160 mg, 1.85 MBq) in a solution. [(14)C]Mirabegron was rapidly absorbed with a plasma t(max) for mirabegron and total radioactivity of 1.0 and 2.3 h postdose, respectively. Unchanged mirabegron was the most abundant component of radioactivity, accounting for approximately 22% of circulating radioactivity in plasma. Mean recovery in urine and feces amounted to 55 and 34%, respectively. No radioactivity was detected in expired air. The main component of radioactivity in urine was unchanged mirabegron, which accounted for 45% of the excreted radioactivity. A total of 10 metabolites were found in urine. On the basis of the metabolites found in urine, major primary metabolic reactions of mirabegron were estimated to be amide hydrolysis (M5, M16, and M17), accounting for 48% of the identified metabolites in urine, followed by glucuronidation (M11, M12, M13, and M14) and N-dealkylation or oxidation of the secondary amine (M8, M9, and M15), accounting for 34 and 18% of the identified metabolites, respectively. In feces, the radioactivity was recovered almost entirely as the unchanged form. Eight of the metabolites characterized in urine were also observed in plasma. These findings indicate that mirabegron, administered as a solution, is rapidly absorbed after oral administration, circulates in plasma as the unchanged form and metabolites, and is recovered in urine and feces mainly as the unchanged form.